Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression
R Singh, SS Rathore, H Khan, S Karale… - Frontiers in …, 2022 - frontiersin.org
Background Obesity affects the course of critical illnesses. We aimed to estimate the
association of obesity with the severity and mortality in coronavirus disease 2019 (COVID …
association of obesity with the severity and mortality in coronavirus disease 2019 (COVID …
[HTML][HTML] Pandemics throughout the history
As we move amidst the coronavirus disease 2019 (COVID-19) pandemic, we have
witnessed tremendous distress, death, and turmoil of everyday life for more than one year …
witnessed tremendous distress, death, and turmoil of everyday life for more than one year …
[HTML][HTML] Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial
S Abd-Elsalam, M Salama, S Soliman… - The American Journal …, 2022 - ncbi.nlm.nih.gov
To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with
COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with …
COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with …
[HTML][HTML] Vaccine development throughout history
The emergence of the coronavirus disease 2019 (COVID-19) pandemic has made us
appreciate how important it is to quickly develop treatments and save lives. The race to …
appreciate how important it is to quickly develop treatments and save lives. The race to …
[HTML][HTML] Acute kidney injury associated with remdesivir: a comprehensive pharmacovigilance analysis of COVID-19 reports in FAERS
B Wu, M Luo, F Wu, Z He, Y Li, T Xu - Frontiers in Pharmacology, 2022 - frontiersin.org
Acute kidney injury (AKI) is a common complication among patients with the novel
coronavirus (COVID-19). COVID-19 along with AKI usually resulted in a poor prognosis for …
coronavirus (COVID-19). COVID-19 along with AKI usually resulted in a poor prognosis for …
Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19)
Background Evidence remains inconclusive on any significant benefits of remdesivir in
patients with mild-to-moderate COVID-19. This study explored the disease progression …
patients with mild-to-moderate COVID-19. This study explored the disease progression …
Remdesivir for the treatment of COVID‐19
Cochrane Haematology Group… - Cochrane Database …, 1996 - cochranelibrary.com
Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19
Aims The aim of this study was to evaluate the safety profile of molnupiravir in COVID‐19
patients. Methods PubMed, Cochrane Library, medRxive and Google Scholar were …
patients. Methods PubMed, Cochrane Library, medRxive and Google Scholar were …
[HTML][HTML] Use and safety of remdesivir in kidney transplant recipients with COVID-19
A Buxeda, C Arias-Cabrales, MJ Pérez-Sáez… - Kidney international …, 2021 - Elsevier
Introduction Remdesivir has demonstrated antiviral activity against coronavirus, shortening
the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse …
the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse …
Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency
Objective To investigate the completeness and currency of published systematic reviews of
remdesivir for COVID-19 and to compare this with a living guidelines approach. Study …
remdesivir for COVID-19 and to compare this with a living guidelines approach. Study …